Skip to main content
Premium Trial:

Request an Annual Quote

FDA Authorizes Pooled Sampling With Applied BioCode Coronavirus Test

NEW YORK — The US Food and Drug Administration on Monday reissued an Emergency Use Authorization for Applied BioCode's SARS-CoV-2 Assay to allow the test to be used with pooled samples.

The PCR-based test, which runs on Applied Biocode's MDx-3000 instrument, was first authorized in June for the detection of two conserved regions in the SARS-CoV-2 N gene in upper respiratory specimens and bronchoalveolar lavage. Under the reissued EUA, the test may also be used with pooled samples containing up to five individual upper respiratory specimens collected by a healthcare provider using individual vials containing transport media. 

With pooled sampling, Santa Fe Springs, California-based Applied BioCode said that its MDx-3000 instrument can run 2,820 samples a day.

Use of the assay is limited to labs CLIA-certified to perform high-complexity tests, according to the FDA.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.